Table I.

Completed/ongoing clinical trials of RC48 in HER2 breast cancer treatment.

A, Completed trials
Study phase	Registration no.	Arms and interventions	Condition	Subjects	Outcomes/status
I	NCT02881138	RC48-ADC	HER2-positive metastatic breast cancer	23	ORR: 72.7% in 11 trastumab pretreated pts; SD: 28.6% in 14 pts at dose ≥1.5 mg/kg; PR: 57.1%.
I	NCT03052634	RC48-ADC	HER2-positive metastatic breast cancer	30	ORR: 36.7%; SD: 60%; CBR: 46.7%.
B, Ongoing studies
Study phase	Registration no.	Arms and interventions	Condition	Subjects	Outcomes/status
II/III	NCT03500380	RC48-ADC vs. Lapatinib + Capecitabine	HER2-positive metastatic breast cancer with or without liver metastases	301	Recruiting
II	NCT03052634	RC48-ADC	Advanced breast cancer with HER2 positive or HER2 low expression	112	Active, not recruiting
III	NCT04400695	RC48-ADC vs. Paclitaxel or Docetaxel or Vinorelbine Tartrate or Capecitabine	HER2 low breast cancer with recurrence/metastasis	366	Recruiting
II	NCT05134519	RC48-ADC	HER2-positive breast cancer	20	Not yet recruiting

ORR, overall response rate; SD, stable disease; PR, partial response; CBR, clinical benefit rate; pts, patients; HER2, human epidermal growth factor receptor 2; ADC, antibody-drug conjugates; RC48, Disitamab Vedotin.